Head-to-head · free
Tempus AI, Inc. vs Twist Bioscience
TEM vs TWST — return on capital, cash generation, margins and balance sheet side by side.
TEM
3 / 6
measures where TEM leads
TWST
3 / 6
measures where TWST leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | TEM · FY2025 | TWST · FY2026 |
|---|---|---|
| Revenue | $1.3B | — |
| Net income | (245.0M) | (130.2M) |
| Revenue growth (yearly, multi-year) | 83.4% | — |
| Free cash flow | (239.1M) | (89.0M) |
| Free cash flow margin | -18.8% | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -89.5% | -16.4% |
| Gross margin | 62.7% | 50.7% |
| Operating margin | -19.9% | -36.2% |
| Net debt / EBITDA | -4.22x | 1.64x |
Figures are as reported by each company; latest fiscal year shown.
Where Tempus AI, Inc.'s cash went (FY2025)
- Capital spending
- $21.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Twist Bioscience's cash went (FY2026)
- Capital spending
- $47.6M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free